Thermo Fisher Scientific Inc. (NYSE:TMO) Position Decreased by Slow Capital Inc.

Slow Capital Inc. trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 7,447 shares of the medical research company’s stock after selling 73 shares during the quarter. Slow Capital Inc.’s holdings in Thermo Fisher Scientific were worth $3,875,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Legacy Investment Solutions LLC purchased a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $26,000. Peterson Financial Group Inc. acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at approximately $27,000. Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Endeavor Private Wealth Inc. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $30,000. Finally, Decker Retirement Planning Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $43,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on TMO. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a “buy” rating and a $680.00 target price on the stock. TD Cowen increased their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Bernstein Bank boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Barclays lowered their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $648.95.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,850 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $557.89, for a total value of $3,263,656.50. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,611,804.88. The trade was a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 34,850 shares of company stock worth $19,123,197. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $583.43 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a 50 day moving average of $533.60 and a 200-day moving average of $569.81. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $223.16 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.